Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 σ receptor gene

Journal of Neurochemistry

Volumn 70, Issue 2, 1998, Pages 443-451

  Prasad, Puttur D ^a   Li, Hui W ^a   Fei, You Jun ^a   Ganapathy, Malliga E ^a,b   Fujita, Takuya ^a   Plumley, Lisa H ^c   Yang Feng, Teresa L ^c   Leibach, Frederick H ^a   Ganapathy, Vadivel ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosomal localization; Exon intron organization; Gene structure; Promoter sequence; receptor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; COMPLEMENTARY DNA; MESSENGER RNA; NUCLEAR FACTOR I; SIGMA OPIATE RECEPTOR;

ARTICLE; CHROMOSOMAL LOCALIZATION; CHROMOSOME 9P; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; GENE SEQUENCE; HUMAN; INTRON; PRIORITY JOURNAL; PROMOTER REGION; TATA BOX;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0031913686     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70020443.x     Document Type: Article

References (37)

1. Axelsson R. and Wahlstrom M. (1984) Chromosome aberrations in patients with paranoid psychosis. Hereditas 100, 29-31.
2. Benson D. A., Boguski M., Lipman D. J., and Ostell J. (1996) Gen-Bank. Nucleic Acids Res. 24, 1-5.
3. Bourrie B., Bouaboula M., Benoit J. M., Derocq J. M., Esclangon M., Le Fur G., and Casellas P. (1995) Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Eur. J. Immunol. 25, 2882-2887.
4. Briggs M. R., Kadonaga J. T., Bell S. P., and Tjian R. (1986) Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234, 47-52.
5. Carayon P., Bouaboula M., Loubet J. F., Bourrie B., Petitpretre G., Le Fur G., and Casellas P. (1995) The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression. Int. J. Immunopharmacol. 17, 753-761.
6. Carr D. J., Mayo S., Wooley T. W., and De Costa B. R. (1992) Immunoregulatory properties of (+)-pentazocine and sigma ligands. Immunology 77, 527-531.
7. Casellas P., Bourrie B., Canat X., Carayon P., Buisson I., Paul R., Breliere J. C., and Le Fur G. (1994) Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J. Neuroimmunol. 52, 193-203.
8. Derocq J. M., Bourrie B., Segui M., Le Fur G., and Casellas P. (1995) In vivo inhibition of endotoxin-induced pro-inflammatory cytokine production by the sigma ligand SR 31747. J. Pharmacol. Exp. Ther. 272, 224-230.
9. Ferris C. D., Hirsch D. J., Brooks B. P., and Snyder S. H. (1991) σ receptors: from molecule to man. J. Neurochem. 57, 729-737.
10. 2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression. J. Biol. Chem. 270, 7551-7557.
11. Hanner M. Moebius F. F., Flandorfer A., Knaus H. G., Striessnig J., Kempner E., and Glossmann H. (1996) Purification, molecular cloning, and expression of the mammalian sigmal-binding site. Proc. Natl. Acad. Sci. USA 93, 8072-8077.
12. Itzhak Y. and Stein I. (1990) Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci. 47, 1073-1081.
13. 125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor. Proc. Natl. Acad. Sci. USA 89, 1393-1397.
14. Kekuda R., Prasad P. D., Fei Y. J., Leibach F. H., and Ganapathy V. (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 229, 553-558.
15. Kumar H. V., McMahon K. J., Allman K. M., McCaffrey B., and Rowan A. (1989) Pericentric inversion chromosome 9 and personality disorder. Br. J. Psychiatry 155, 408-410.
16. Lee W., Mitchell P., and Tjian R. (1987) Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49, 741-752.
17. Levant B. and Nemeroff C. B. (1990) Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. J. Pharmacol. Exp. Ther. 254, 330-335.
18. Liu Y., Whitlock B. B., Pultz J. A., and Wolf S. A. (1995) Sigma-1 receptors modulate functional activity of rat splenocytes. J. Neuroimmunol. 59, 143-154.
19. Martin W. R., Eades C. G., Thompson J. A., Huppler R. E., and Gilbert P. E. (1976) The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532.
20. Moebius F. F., Burrows G. G., Striessnig J., and Glossmann H. (1993a) Biochemical characterization of a 22-kDa high affinity antiischemic drug-binding polypeptide in the endoplasmic reticulum of guinea pig liver: potential common target for antiischemic drug action. Mol. Pharmacol. 43, 139-148.
21. Moebius F. F., Burrows G. G., Hanner M., Schmid E., Striessnig J., and Glossmann H. (1993b) Identification of a 27-kDa high affinity phenylalkylamine-binding polypeptide as the sigma 1 binding site by photoaffinity labeling and ligand-directed antibodies. Mol. Pharmacol. 44, 966-971.
22. Moebius F. F., Striessnig J., and Glossmann H. (1997) The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 18, 67-70.
23. Nanko S., Kunugi H., Sasaki T., Fukuda R., Kawate T., and Kazamatsuri H. (1993) Pericentric region of chromosome 9 is a possible candidate region for linkage study of schizophrenia. Biol. Psychiatry 33, 655-658.
24. Nanko S., Fukuda R., Hattori M., Sasaki T., Dai X. Y., Gill M., Kuwata S., Shibata Y., and Kazamatsuri H. (1994) No evidence of linkage or allelic association of schizophrenia with DNA markers at pericentric region of chromosome 9. Biol. Psychiatry 36, 589-594.
25. Paonessa G., Gounari F., Frank R., and Cortese R. (1988) Purification of a NF1-like DNA-binding protein from rat liver and cloning of the corresponding cDNA. EMBO J. 7, 3115-3123.
26. Pugh B. F. and Tjian R. (1990) Mechanism of transcriptional activation by Sp1: evidence for coactivators. Cell 61, 1187-1197.
27. Ramamoorthy J. D., Ramamoorthy S., Mahesh V. B., Leibach F. H., and Ganapathy V. (1995) Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. Endocrinology 136, 924-932.
28. Rao P. A. (1997) Review of gene mapping and molecular genetic studies of schizophrenia. Psychiatr. Ann. 27, 279-284.
29. Shaper N. L., Lin S. P., Joziasse D. H., Kim D. Y., and Yang-Feng T. L. (1991) Assignment of two human alpha-1,3-galactosyl-transferase gene sequences (GGTA14 and GGTA1P) to chromosomes 9q33-q34 and 12q14-q15. Genomics 12, 613-615.
30. Sharkey J., Glen K. A., Wolfe S., and Kuhar M. J. (1988) Cocaine binding at sigma receptors. Eur. J. Pharmacol. 149, 171-174.
31. Silve S., Dupuy P. H., Labit-Lebouteiller C., Kaghad M., Chalon P., Rahier A., Taton M., Lupker J., Shire D., and Loison G. (1996) Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits delta8-delta7 sterol isomerase activity in yeast. J. Biol. Chem. 271, 22434-22440.
32. Su T. P. (1991) Sigma receptors. Putative links between nervous, endocrine and immune systems. Eur. J. Biochem. 200, 633-642.
33. Wachtel S. R. and White F. J. (1988) Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. J. Pharmacol. Exp. Ther. 244, 410-416.
34. Walker J. M., Bowen W. D., Walker F. O., Matsumoto R. R., DeCosta R. R., and Rice K. C. (1990) Sigma receptors: biology and function. Pharmacol. Rev. 42, 355-402.
35. Weissman A. D., Casanova M. F., Kleinman J. E., London E. D., and De Souza E. B. (1991) Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol. Psychiatry 29, 41-54.
36. Williams T. and Tjian R. (1991) Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev. 5, 670-682.
37. Witkin J. M. (1994) Pharmacotherapy of cocaine abuse: preclinical development. Neurosci. Behav. Rev. 18, 121-142.